See more : FBC Holding, Inc. (FBCD) Income Statement Analysis – Financial Results
Complete financial analysis of Akili, Inc. (AKLI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Akili, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Roscan Gold Corporation (ROS.V) Income Statement Analysis – Financial Results
- Adit EdTech Acquisition Corp. (ADEX) Income Statement Analysis – Financial Results
- Pharmacolog i Uppsala AB (publ) (PHLOG-B.ST) Income Statement Analysis – Financial Results
- BRB – Banco de Brasília S.A. (BSLI4.SA) Income Statement Analysis – Financial Results
- CIIG Capital Partners II, Inc. (CIIGU) Income Statement Analysis – Financial Results
Akili, Inc. (AKLI)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.akiliinteractive.com
About Akili, Inc.
Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.68M | 323.00K | 538.00K | 3.94M | 19.99M |
| Cost of Revenue | 819.00K | 441.00K | 355.00K | 416.00K | 1.34M |
| Gross Profit | 859.00K | -118.00K | 183.00K | 3.52M | 18.64M |
| Gross Profit Ratio | 51.19% | -36.53% | 34.01% | 89.44% | 93.29% |
| Research & Development | 19.93M | 28.86M | 18.23M | 15.42M | 21.27M |
| General & Administrative | 38.84M | 53.84M | 29.78M | 13.54M | 18.88M |
| Selling & Marketing | 6.58M | 7.86M | 12.89M | 0.00 | 0.00 |
| SG&A | 45.42M | 61.70M | 42.67M | 13.54M | 18.88M |
| Other Expenses | 4.04M | 82.73M | 17.00K | 124.00K | 1.03M |
| Operating Expenses | 65.34M | 90.56M | 60.90M | 28.96M | 40.14M |
| Cost & Expenses | 66.16M | 91.00M | 61.26M | 29.38M | 41.48M |
| Interest Income | 0.00 | 1.48M | 8.32K | 333.00K | 157.00K |
| Interest Expense | 2.36M | 1.48M | 465.00K | 333.00K | 157.00K |
| Depreciation & Amortization | 302.00K | 308.00K | 296.00K | 424.00K | 1.29M |
| EBITDA | -60.14M | -88.89M | -60.44M | -25.01M | -20.21M |
| EBITDA Ratio | -3,584.21% | -28,073.37% | -11,231.04% | -634.98% | -101.14% |
| Operating Income | -64.49M | -90.68M | -60.72M | -25.44M | -21.50M |
| Operating Income Ratio | -3,842.97% | -28,073.37% | -11,286.06% | -645.75% | -107.57% |
| Total Other Income/Expenses | 5.05M | 82.73M | -629.00K | -209.00K | 877.00K |
| Income Before Tax | -59.49M | -7.95M | -61.35M | -25.65M | -20.62M |
| Income Before Tax Ratio | -3,545.47% | -2,459.75% | -11,402.97% | -651.05% | -103.18% |
| Income Tax Expense | 53.00K | 19.00K | 482.00K | 1.00K | 13.00K |
| Net Income | -59.49M | -7.96M | -61.83M | -25.65M | -20.63M |
| Net Income Ratio | -3,545.47% | -2,465.63% | -11,492.57% | -651.08% | -103.24% |
| EPS | -0.76 | -0.27 | -1.94 | -0.33 | -0.27 |
| EPS Diluted | -0.76 | -0.27 | -1.94 | -0.33 | -0.27 |
| Weighted Avg Shares Out | 78.20M | 29.88M | 31.89M | 77.86M | 77.86M |
| Weighted Avg Shares Out (Dil) | 78.20M | 29.88M | 31.89M | 77.86M | 77.86M |
Akili Reports Second Quarter 2023 Financial Results and Provides Business Update
BOSTON--(BUSINESS WIRE)--Akili Reports Second Quarter 2023 Financial Results and Provides Business Update.
Akili to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10 at 4:30 p.m. ET
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the second quarter of 2023 on Thursday, August 10, 2023, at 4:30 p.m. ET. A...
Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress
BOSTON--(BUSINESS WIRE)---- $AKLI #ADHD--Akili To Presents Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at Upcoming Scientific Meetings.
Akili Reports First Quarter 2023 Financial Results and Provides Business Update
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter ended March 31, 2023, and provided an update on business progress. “We’re seeing steady, increasing uptake of EndeavorRx in the pediatric market,”...
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company noted today that its Founded Entity, Akili, Inc. (Nasdaq: AKLI) (“Akili”), a leading digital medicine company, announced topline results of the STARS-ADHD-Adult clinical trial...
Why Is Akili (AKLI) Stock Up 21% Today?
Akili (NASDAQ: AKLI ) stock is gaining on Wednesday after the company's video game treatment showed success in reducing ADHD in adults. Akili's EndeavorRx treatment uses video games to treat patients who deal with the effects of ADHD.
Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced topline results of the STARS-ADHD-Adult clinical trial evaluating the efficacy and safety of EndeavorRxⓇ (AKL-T01) in adults with attention-deficit/hyperactivity disorder (ADHD). STARS-ADHD-Adult was designed as a pivotal clinical...
Akili to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 11 at 4:30 p.m. ET
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the first quarter of 2023 on Thursday, May 11, 2023, at 4:30 p.m. ET. A...
Akili, Inc. (AKLI) Q4 2022 Earnings Call Transcript
Akili, Inc. (NASDAQ:AKLI ) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Julie DiCarlo - Senior Vice President of Communications Eddie Martucci - Co-Founder, CEO & Director Matthew Franklin - President & COO Scott Kollins...
Akili Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter and full year ended December 31, 2022, and provided an update on business progress. “We have established a focused and efficient operating...
Source: https://incomestatements.info
Category: Stock Reports